/ Unknown statusPhase 1/2 A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease
This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease
/ Unknown statusPhase 1/2 A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)
The purpose of this study is to determine the initial safety, tolerability and pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC
100 Clinical Results associated with Fast Forward Pharmaceuticals BV
0 Patents (Medical) associated with Fast Forward Pharmaceuticals BV
100 Deals associated with Fast Forward Pharmaceuticals BV
100 Translational Medicine associated with Fast Forward Pharmaceuticals BV